|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Inflammation in Drug Discovery & Development | ||||||||||||||||
| November 06, 2002 | ||||||||||||||||
|
Strategic Research Institute, Wyndham Emerald Plaza, San Diego, CA, USA February 20 - 21, 2003 ORGANIZED INTO FOUR SECTIONS: 1) NOVEL ANTI-TNF PROTEINS & SMALL MOLECULE INHIBITORS 2) ADVANCES IN IL-1, GAMMA INTERFERON & IL-2 BIOLOGICS 3) NOVEL B CELL, T CELL & RECEPTOR MODULATORS 4) ADDITIONAL APPROACHES FOR NOVEL ANTI-INFLAMMATORY DRUGS |
||||||||||||||||
| Organized by: | Ed Drilon | |||||||||||||||
| Invited Speakers: | Discovery of Orally Active TNF Convertase Inhibitors as Anti-Rheumatoid Arthritis Drugs AMGEN Challenges in the Discovery and Development of Novel Chemokine Antagonists MILLENNIUM PHARMACEUTICALS Discovery of Novel LFA-1 Antagonists BOEHRINGER INGELHEIM PHARMACEUTICALS Rituxan®/MabThera® as a Novel Antirheumatic Therapy ROCHE BIOSCIENCE Kinase Inhibitors RW JOHNSON, CELGENE & BRISTOL-MYERS SQUIBB |
|||||||||||||||
| Deadline for Abstracts: | tbd | |||||||||||||||
| Registration: | www.srinstitute.com | |||||||||||||||
| E-mail: | edrilon@srinstitute.com | |||||||||||||||
| Posted by: | Jennifer Law | |||||||||||||||
| Host: | 12.3.58.15 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||